20 May 2013
Keywords: Targeted cancer drugs, Fatal side effect risks, Nexavar, Sutent, Votrient
Article | 08 February 2012
Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 February 2012
17 May 2013
© 2013 thepharmaletter.com